The same technology that produced the COVID-19 vaccines in record time has just cleared its most significant hurdle yet in cancer treatment. Moderna and Merck announced this week that their personalized mRNA cancer vaccine — called Intismeran — succeeded in its first-ever Phase 3 clinical trial, reducing the risk of melanoma returning and spreading in patients who had their cancer surgically removed.
Moderna's stock surged 90%. Merck's climbed 10%. Moderna CEO Stéphane Bancel said on CNBC: "It's a big moment for medicine, a big moment for patients."
What the Trial Actually Found
The trial enrolled 1,137 patients with higher-risk or advanced melanoma — the deadliest form of skin cancer, responsible for the large majority of skin cancer deaths despite accounting for only about 1% of cases. All patients had their detectable cancer completely removed through surgery. They were then randomly assigned to receive either Intismeran combined with Merck's immunotherapy drug Keytruda, or Keytruda alone.
The combination met both of its primary goals. Patients who received the mRNA vaccine alongside Keytruda lived significantly longer without their melanoma returning, compared to those who received Keytruda alone. The vaccine also reduced the risk of cancer spreading to distant parts of the body — a critical measure, since metastatic melanoma is dramatically harder to treat than localized disease.
This is the first randomized Phase 3 trial ever to definitively demonstrate that a personalized neoantigen cancer vaccine works at this scale. It took decades of cancer immunology research, a platform technology refined through COVID, and a partnership between two of the world's largest pharmaceutical companies to get here.
What "Personalized" Actually Means
Intismeran is not a single vaccine given to every melanoma patient. It is built individually for each person, which is what makes it both revolutionary and logistically unprecedented.
After a patient's tumor is surgically removed, researchers sequence its genetic code to identify mutations unique to that specific cancer. The vaccine is then manufactured to train the patient's immune system to recognize and attack cells carrying those specific mutations. A different patient with melanoma gets a different vaccine.
This approach — called neoantigen therapy — targets the fingerprint of an individual tumor rather than a shared characteristic of a cancer type. It is the personalized medicine concept that oncologists have talked about for twenty years, now demonstrated to work in a large, randomized, controlled trial.
The manufacturing timeline required to produce a personalized vaccine for each patient is one of the central challenges of scaling this approach. Moderna has been building out the infrastructure needed to do this at volume. The Phase 3 result dramatically accelerates that investment case.
Why the COVID Technology Changed Everything
Before mRNA vaccines, the idea of building a personalized cancer vaccine for each patient would have been logistically impossible at commercial scale. Traditional vaccine manufacturing is slow. mRNA manufacturing is fast — the sequence can be designed computationally and translated into a vaccine in weeks rather than months.
The COVID pandemic forced a massive investment in mRNA manufacturing infrastructure and proved the platform could work at global scale. That infrastructure now exists. Moderna and Merck used it to manufacture individualized cancer vaccines for over a thousand trial participants — a feat that would have been unthinkable a decade ago.
"While we need to await the final results, this early report is certainly promising and builds on the encouraging results that have been observed across smaller studies over the past decade," said Catherine Wu, an oncologist at Dana-Farber Cancer Institute.
What Comes Next — and for Which Cancers
Merck's R&D head Dean Li said the companies expect to begin regulatory talks in the coming months. Analysts estimate the melanoma vaccine could generate approximately $3 billion annually by 2035 if approved.
But melanoma is the beginning. Moderna and Merck are currently running trials of the same vaccine approach in non-small cell lung cancer, bladder cancer, and renal cell carcinoma. Analysts covering the companies say their valuations already reflect expectations that this approach could eventually work across multiple cancer types — a possibility that, for the first time, has Phase 3 clinical data behind it.
The phase three trial is ongoing, and the companies have not yet released overall survival data — the gold standard measure of whether a cancer treatment actually extends lives. That data will take years to accumulate. What exists now is the proof that the approach works well enough to clear the regulatory bar for efficacy.
That is not a small thing. For forty years, personalized cancer immunotherapy was a scientific hope. This week it became a demonstrated result.
